Evidence map›Paper›PMID 35499056›Full record

ArticleJournal of advanced research2022

Leucine-rich repeat kinase-2 deficiency protected against cardiac remodelling in mice via regulating autophagy formation and degradation.

Yuan Liu, Congqing Hao, Wei Zhang, Yuzhou Liu, Sen Guo, Ran Li, Meng Peng, Yawei Xu, Xiaoxin Pei, Haibo Yang and 1 more

Open access · goldAbstract read
In one paragraph

Article in Journal of advanced research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Novel Therapeutic Avenues for Hypertrophic Cardiomyopathy.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2023
    Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Yuan LiuDepartment of Cardiology, The First Affliated Hospital of Zhengzhou University, No.1 Jianshe East Road, Zhengzhou, China.
Congqing HaoDepartment of Cardiology, The First Affliated Hospital of Zhengzhou University, No.1 Jianshe East Road, Zhengzhou, China.
Wei ZhangDepartment of Anaesthesiology, The First Affliated Hospital of Zhengzhou University, Zhengzhou, China.
Yuzhou LiuDepartment of Cardiology, The First Affliated Hospital of Zhengzhou University, No.1 Jianshe East Road, Zhengzhou, China.
Sen GuoDepartment of Cardiology, The First Affliated Hospital of Zhengzhou University, No.1 Jianshe East Road, Zhengzhou, China.
Ran LiDepartment of Cardiology, The First Affliated Hospital of Zhengzhou University, No.1 Jianshe East Road, Zhengzhou, China.
Meng PengDepartment of Cardiology, The First Affliated Hospital of Zhengzhou University, No.1 Jianshe East Road, Zhengzhou, China.
Yawei XuDepartment of Cardiology, The First Affliated Hospital of Zhengzhou University, No.1 Jianshe East Road, Zhengzhou, China.
Xiaoxin PeiDepartment of Cardiology, The First Affliated Hospital of Zhengzhou University, No.1 Jianshe East Road, Zhengzhou, China.
Haibo YangDepartment of Cardiology, The First Affliated Hospital of Zhengzhou University, No.1 Jianshe East Road, Zhengzhou, China.
Yintao ZhaoDepartment of Cardiology, The First Affliated Hospital of Zhengzhou University, No.1 Jianshe East Road, Zhengzhou, China.
First Affiliated Hospital of Zhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Leucine-rich repetitive kinase-2 (LRRK2) is a Parkinson's disease-related gene that also participates in many inflammatory diseases. However, the functional role of LRRK2 in cardiovascular disease is not clear. Objective: In this study, we aimed to elucidate the role of LRRK2 in cardiac remodelling under pressure overload. Methods: Aortic banding surgery was performed to induce cardiac remodelling in a LRRK2 knockout mouse model. A cardiomyocyte remodelling model was established by phenylephrine (PE) stimulation in neonatal rat cardiomyocytes. Results: LRRK2 was upregulated in remodelled mouse hearts and cardiomyocytes. Cardiac hypertrophy, fibrosis and dysfunction were ameliorated in LRRK2 knockout mice. LRRK2 silencing protected against the PE-induced cardiomyocyte hypertrophic response, while LRRK2 over-expression worsened the PE-induced hypertrophic response in cardiomyocytes. Decreased autophagy was observed in remodelled cardiomyocytes, whereas LRRK2 silencing increased autophagy levels and LRRK2 overexpression reduced autophagy levels. The autophagy inhibitors 3-MA, bafilomycin and chloroquine reversed the protective effects of LRRK2 deficiency. The autophagy activator rapamycin reversed the deleterious effects of LRRK2 overexpression. We found that LRRK2 inhibited Bcl-2 phosphorylation, thus decreasing the phosphorylation of Beclin1. The protective effects of LRRK2 knockout were partly counteracted by Beclin1(+/-) Conclusion: LRRK2 deficiency protected against cardiac remodelling under pressure overload by increasing Bcl-2/Beclin1 and Rab7-regulated autophagy levels in the heart.

Indexed as

AutophagyVentricular RemodelingAnimalsBeclin-1LeucineLeucine-Rich Repeat Serine-Threonine Protein Kinase-2MiceMice, KnockoutProto-Oncogene Proteins c-bcl-2RatsBeclin-1LeucineLeucine-Rich Repeat Serine-Threonine Protein Kinase-2Lrrk2 protein, mouseProto-Oncogene Proteins c-bcl-2AutophagyBcl-2Beclin1Cardiac remodellingLeucine-rich repeat kinase-2Rab7

Identifiers

PMID35499056
PMCPMC9039674
OpenAlexW3178382813

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.